Advertisement

Interleukin-10 inhibits ovarian cancer cells growth via down regulation of inflammatory cytokine production

American Journal of BioMedicine  Volume 2, Issue 8, pages 940-951, August 2014


Xi Wang; Shuhe Yang; Erin Zheng; Paul Xiao; Zheng-Yu Li

Abstract

Ovarian cancer is the most lethal type of gynecologic cancer in the Western world. The high case fatality rate is due in part because most ovarian cancer patients present with advanced stage disease which is essentially incurable. Unfortunately, only a quarter of ovarian cancer patients are diagnosed as stage I. For this reason, considerable efforts have been devoted to the search of novel ovarian cancer markers. Interleukin-10 (IL-10) is a broadly acting immune inhibitory cytokine that is generally thought to support tumor growth. Here, we investigated the regulation of IL-10 expression in normal and cancer ovarian surface epithelial cells. A total of 1 × 293 ovarian cancer cells were inoculated subcutaneously into the left flank of IL-10−/−, IL-10+/+ C57BL/6 background mice. Ovarian cancer cells had accelerated growth in IL-10−/− mice as compared with IL-10+/+ mice as shown by tumor volume measurement. Further, the percentages of intratumoral Treg cells during the course of tumor development were higher in IL-10−/− mice as compared with their wild-type counterparts beginning on day 12. In addition, presenting data showed that myeloid cells from tumor-free mice expressed higher levels of IL-1α and IL-1β in IL-10−/− than IL-10+/+ mice. While the roles of IL-10 in ovarian malignant transformation remain unclear, we propose that IL-10 may represent alternative targets for diagnosis and therapy and of this deadly disease.

Keywords: Ovarian cancer; Treg cells; IL-10; Inflammatory cytokine


Limited Access               HTML                 Full Text-PDF                Feedback


References

1. Lengyel E. Ovarian cancer development and metastasis. Am J Pathol 2010;177: 1053–1064. [PubMed]

2. Adib TR, Henderson S, Perrett C, Hewitt D, Bourmpoulia D, et al. Predicting biomarkers for ovarian cancer using gene-expression microarrays. Br J Cancer 2004; 90: 686–692. [PubMed]

3. Lancaster JM, Dressman HK, Clarke JP, Sayer RA, Martino MA, et al. Identification of genes associated with ovarian cancer metastasis using microarray expression analysis. Int J Gynecol Cancer 2006; 16: 1733–1745. [PubMed]

4. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005; 33: e179. [PubMed]

5. Grun B, Benjamin E, Sinclair J, Timms JF, Jacobs IJ, et al. Three-dimensional in vitro cell biology models of ovarian and endometrial cancer. Cell Prolif 2009; 42: 219–228. [PubMed]

6. Rahmanzadeh R, Rai P, Celli JP, Rizvi I, Baron-Luhr B, et al. Ki-67 as a molecular target for therapy in an in vitro three-dimensional model for ovarian cancer. Cancer Res 2010; 70: 9234–9242. [PubMed]

7. Yousif NG. Fibronectin promotes migration and invasion of ovarian cancer cells through up‐regulation of FAK–PI3K/Akt pathway. Cell biology international 2013; 38(1): 85-91. [Abstract/FREE Full Text]

8. Shield K, Ackland ML, Ahmed N, Rice GE. Multicellular spheroids in ovarian cancer metastases: Biology and pathology. Gynecol Oncol 2009; 113: 143–148. [PubMed]

9. Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 2006;203:871–81. [Abstract/FREE Full Text]

10. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001;19:683–765. [PubMed]

11. Hagenbaugh A, Sharma S, Dubinett SM, Wei SH, Aranda R, Cheroutre H, et al. Altered immune responses in interleukin 10 transgenic mice. J Exp Med 1997;185:2101–10. [Abstract/FREE Full Text]

12. Lang R, Patel D, Morris JJ, Rutschman RL, Murray PJ. Shaping gene expression in activated and resting primary macrophages by IL-10. J Immunol 2002;169:2253–63. [Abstract/FREE Full Text]

13. Neuzillet JM, Traynor C, Hullmann G, Tyritzis G, Shimizu J. TNF-α-induced IL-32 expression in esophageal cancer: cross talk JNK/Akt signaling pathways. American Journal of BioMedicine 2013;1(2):73-85. [Abstract/FREE Full Text]

14. Wang DG, Yousif NG, Sadiq AM, Schilling MM,  Danielson AJ. Critical role of SEMA5A expression in invasion and metastasis of ovarian cancer cell. American Journal of BioMedicine 2014;2:292–305. [Abstract/FREE Full Text]

15. Sinha P, Clements VK, Ostrand-Rosenberg S. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol 2005;174:636–45. [Abstract/FREE Full Text]

16. Groux H, Bigler M, de Vries JE, Roncarolo MG. Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells. J Immunol 1998;160:3188–93. [Abstract/FREE Full Text]

17. Tilg H, van Montfrans C, van den Ende A, Kaser A, van Deventer SJ, Schreiber S, et al.Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. Gut 2002; 50:191–5. [Abstract/FREE Full Text]

18. Krelin Y, Voronov E, Dotan S, Elkabets M, Reich E, Fogel M, et al. Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. Cancer Res 2007;67:1062–71. [Abstract/FREE Full Text]

19. Tanikawa T, Wilke CM, Kryczek I, Chen GY, Kao J, Núñez G, Zou W. Interleukin-10 Ablation Promotes Tumor Development, Growth, and Metastasis. Cancer Res 2012; 72:420-429. [Abstract/FREE Full Text]

20. Cyktor JC, Turner J. Interleukin-10 and Immunity against Prokaryotic and Eukaryotic Intracellular Pathogens Infect. Immun 2011; 79:2964-2973. [Abstract/FREE Full Text]

21. Alhasani S, Yousif  NG. Critical role of IL-23 signaling in prostatic cancer. American Journal of BioMedicine 2013;1:4-6. [Abstract/FREE Full Text]

22. Bogdan C, Vodovotz Y, Nathan C. Macrophage deactivation by interleukin 10. J. Exp. Med 1991;174:1549–1555. [Abstract/FREE Full Text]

23. Chmiel JF, et al. Prolonged inflammatory response to acute Pseudomonas challenge in interleukin-10 knockout mice. Am. J. Respir. Crit. Care Med 2002; 165:1176–1181. [Abstract/FREE Full Text]

24. Deepe GS, Gibbons RS. Protective and memory immunity to Histoplasma capsulatum in the absence of IL-10. J. Immunol 2003;171:5353–5362. [Abstract/FREE Full Text]

25. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J. Exp. Med 1991; 174:1209–1220. [Abstract/FREE Full Text]

26. Dhingra S, Sharma AK, Arora RC, Slezak J, Singal PK. IL-10 attenuates TNF-alpha-induced NF kappaB pathway activation and cardiomyocyte apoptosis. Cardiovasc. Res 2009;  82:59–66. [Abstract/FREE Full Text]

27. Yang X, Gartner J, Zhu L, Wang S, Brunham RC. IL-10 gene knockout mice show enhanced Th1-like protective immunity and absent granuloma formation following Chlamydia trachomatis lung infection. J. Immunol 1999; 162:1010–1017. [Abstract/FREE Full Text]

American Journal of Biomedicine © 2017 Frontier Theme
%d bloggers like this: